- >120 biologics in R&D
- ~2,200 global employees
- 50% of AstraZeneca's pipeline
Leading global biologics R&D
With one of the largest, most robust pipelines in the industry — including more than 120 research projects and product candidates — we comprise nearly half of AstraZeneca’s overall R&D portfolio. We are focused on three core therapeutic areas: Oncology; Respiratory, Inflammation and Autoimmune; and Cardiovascular and Metabolic Disease. But, we also are opportunity-driven in Infectious Disease.
In addition to having more than 600 employees, MedImmune, Cambridge, has strong collaborative links with numerous academics, researchers, foundations and neighboring companies in Europe's largest biotech cluster.
A modern and vibrant science campus employs more than 2,000 industry experts and sits amid a strong and growing biotech hub–and is only a short drive from Washington, DC.
Our state-of-the-art facility in the Cove at Oyster Point is located in the heart of the Bay Area’s vibrant biotechnology and technology community.